Co-hosted with the ISPOR Asia Consortium, this webinar helps Chinese hospital decision-makers measure the costs and benefits associated with their ASP.
The value of antimicrobial stewardship programs (ASPs) have not been fully studied; and there is a lack of an established ASP value evaluation framework in China. Therefore, this webinar aims to present a study contributing to the development of a comprehensive China-specific ASP evaluation framework informed by U.S. guidelines and adapted to unique characteristics of Chinese ASPs. The webinar speakers will guide Chinese and other hospital decision makers on ways to accurately measure the costs and benefits associated with their specific ASP. Overall, this webinar provides strategies to improve the implementation of ASPs in China as well as programs in other world regions.
Learn about open access global educational programs that support development, implementation, and measurement of ASPs
Understand the importance of ASPs in the Chinese National Action Plan to reduce AMR and how industry, such as Pfizer, is addressing these initiatives
Gain an understanding of the importance of standardized measurement, particularly in evaluating the clinical and economic impact of ASPs
Obtain an understanding of the methodology used to create an ASP evaluation framework for China, and subsequent model development
Get acquainted with interactive tools that can be used to collect data, validate, and communicate results
Cindy (Xin) Gao, PhD, Principal and Asia-Pacific Regional Lead; Pharmerit International, Bethesda, USA
Xin (Cindy) Gao is Asia-Pacific Regional Lead of Pharmerit International as well as a Partner of Pharmerit (Shanghai) Company Limited (傅盟医药咨询（上海）有限公司), and is based in our Bethesda, MD office. Dr. Gao has more than 17 years of experience in HEOR consulting, previous working at PPD and Abt Associates. She is experienced in preparing and submitting pharmaceutical product assessments to HTA authorities. She has considerable experience at building market-relevant health economic models; designing and implementing prospective health economic and outcomes trial studies; and conducting strategic market access projects. She has also worked on many real-world studies from claims/EMR database analyses to chart reviews and survey studies. Dr. Gao holds a B.S. in Pharmaceutical Sciences from China Pharmaceutical University and a PhD in Pharmaceutical Economics and Health Policy from West Virginia University School of Pharmacy.
Emily Yixi Chen, MSc, HEOR Manager; Pfizer Investment Co. Ltd., Beijing, China.
Emily (Yixi) Chen is Senior Manager of Health Economics and Outcomes Research (HEOR) at Pfizer China. During her 6+ years with the company, she has been leading numerous HEOR projects in various therapeutic areas, including infectious diseases, cardiovascular diseases, inflammation & immuology, rare diseases, etc. She is seasoned in economic evaluation of healthcare programs as well, e.g. antimicrobial stewardship programs and city immunization programs. She led the development of a new concept of Precision HEOR and the associated big-data-based methodology for generating novel evidence to support optimizing healthcare resource allocation. She also gained solid experience in market access, pricing and reimbursement strategy setting when she worked as a consultant at Simon-Kucher & Partners before joining Pfizer.
She received her BSc (cum laude) of Biology from Sichuan University, China, and MSc (cum laude) of Medical and Pharmaceutical Drug Innovation from Groningen University, the Netherlands, where she specialized in Microbiology and Toxicology. Her second MSc in International Healthcare Management, Economics and Policy was obtained from SDA Bocconi, Italy.
Seema Haider, PhD, Senior Director, Group Lead PEH HEOR; Pfizer Inc., New York, USA
Seema Haider has over twenty-three years of experience in leading and managing international, multidisciplinary teams for the lifetime management of developing and executing Outcomes Research (OR) and Access Product and Therapeutic Area Portfolio strategies, studies and publications. Seema received her MSc in Social and Preventive Medicine from University of Montreal in 1992. From 1993 through1995, Seema completed PhD course work in Social and Preventive Medicine, specializing in Pharmacoeconomics, led a prospective, multicenter, Pharmacoeconomics substudy in COPD patients at the Randomized Clinical trial Unit at McGill University and was Project Director at the Interdisciplinary Health Research Group, Heath economics Unit at the University of Montreal. From 1995 to 1998, Seema was Country Manager of Pharmacoeconomics and Quality of Life Research at Schering Plough Canada for all products. Seema joined Pfizer Inc., 20 years ago and with escalating leadership positions, she currently leads Health Economics and Outcomes Research, Patient & Health Impact, for the Pfizer Essential Health Business Unit. Her work has been extensively presented and featured at conferences worldwide and in publications in high impact peer reviewed journals. Seema has also contributed to several training initiatives worldwide including, the IFAPP-King’s College London Medical Affairs in Medicines Development Professional Certification Program and the Asian Institute of Management in the Philippines. She is also an International Advisor to the ISPOR India Chapter and holds a Visiting Professorship at the Public Health & Health Economics Research Center at Hebei University in China (2017-2020).
About the Co-hosting Institution:
ISPOR is a professional society for health economics and outcomes research, with the mission of promoting excellence in this field to improve decision making for health globally. This society is a multistakeholder organization with over 20,000 individual and chapter members worldwide.
The ISPOR Asia Consortium is a member group comprised of professionals interested in the ISPOR mission in Asia-Pacific and globally. The Consortium provides a platform for information-sharing and institutional collaboration on HEOR and health policy, facilitating professional networking opportunities through scientific activities and global ISPOR initiatives.